Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2076)	1/4/2008 10:27:27 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

HGSI is trading above the 11.50 level, up around 5.4% bigcharts.marketwatch.com It announced today that it will present at the 26th Annual JPMorgan Healthcare Conference on Wednesday, Jan 9 in Frisco. HGSI had an "upgrade" this week & some favorable comments about its drug development programs for hepatitis C and lupus & its artherosclerosis drug candidate Darapladib, which have the potential to generate royalties. Besides Darapladib, its diabetes drug candidate Syncria seems to be the next most promising product, with future royalties for sales estimated by some at 10% & with about $183M in milestone payments. It is also expected that HGSI will announce its first sales of ABthrax. for treatment of anthrax in late 2008. I will keep a modest "target" for HGSI around $15.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2076)	1/7/2008 11:56:23 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

OSIR Is closing Friday's UG bigcharts.marketwatch.com In spite of better revenues, it has continued to report higher losses & the EL for 2007 is around $1.50 vs. $1.37 i9n 2006 & for 2008 the EL is still around $1.05 GENZ, which will receive a royalty of 15% of net product sales of OSIR's Prochymal is acting better, as it seems that it wants to retest its all time H of $77.51 it had on Friday.<g> bigcharts.marketwatch.com GENZ has 4Qs of double digit improvements on revenues & the earnings have also improved at a double digit pace.The EE for 2007 are around $3.45 vs, $2.77 in 2006 & for 2008 a further improvement to $4 is expected. The stock trades around 3.5xBV; has a +CF around $4 & short ratio close to 3x its ADV The DOW & the NAZ have improved in the last 45 minutes & with better market conditions, GENZ could trade at the $85 level this Yr.<g> bigcharts.marketwatch.com Bernard